POSTER 18

Long-term Efficacy and Safety of Lebrikizumab Is Maintained in Patients with Moderate-to-Severe Atopic Dermatitis: Results Up to 3 Years from Adjoin

Emma Guttman-Yassky, Alan Irvine, Eric Simpson, Melinda Gooderham, Stephan Weidinger, Lynda Spelman, Jonathan Silverberg, Heidi Crane, Hany Elmaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Chaoran Hu, Evangeline Pierce, Helena Agell, Diamant Thaci

< Previous Poster | Next Poster >

Poster 18